Skip to main content

Main menu

  • HOME
  • ARTICLES
    • Current Issue
    • Abstracts In Press
    • Archives
    • Special Issue Archive
    • Subject Collections
  • INFO FOR
    • Authors
    • Reviewers
    • Call For Papers
    • Subscribers
    • Advertisers
  • SUBMIT
    • Manuscript
    • Peer Review
  • ABOUT
    • The JABFM
    • The Editing Fellowship
    • Editorial Board
    • Indexing
    • Editors' Blog
  • CLASSIFIEDS
  • Other Publications
    • abfm

User menu

Search

  • Advanced search
American Board of Family Medicine
  • Other Publications
    • abfm
American Board of Family Medicine

American Board of Family Medicine

Advanced Search

  • HOME
  • ARTICLES
    • Current Issue
    • Abstracts In Press
    • Archives
    • Special Issue Archive
    • Subject Collections
  • INFO FOR
    • Authors
    • Reviewers
    • Call For Papers
    • Subscribers
    • Advertisers
  • SUBMIT
    • Manuscript
    • Peer Review
  • ABOUT
    • The JABFM
    • The Editing Fellowship
    • Editorial Board
    • Indexing
    • Editors' Blog
  • CLASSIFIEDS
  • JABFM on Bluesky
  • JABFM On Facebook
  • JABFM On Twitter
  • JABFM On YouTube
Research ArticleOriginal Research

Factors That Influence Treatment Completion for Latent Tuberculosis Infection

McKenna C. Eastment, Adelaide H. McClintock, Christy M. McKinney, Masahiro Narita and Alexandra Molnar
The Journal of the American Board of Family Medicine July 2017, 30 (4) 520-527; DOI: https://doi.org/10.3122/jabfm.2017.04.170070
McKenna C. Eastment
From the Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington School of Medicine, Seattle (ME); the Division of General Internal Medicine, Department of Medicine, University of Washington School of Medicine, Seattle (AHM, AM); the Department of Oral Health Sciences, University of Washington School of Dentistry, Seattle (CMM); the Division of Pulmonary & Critical Care Medicine, Department of Medicine, University of Washington School of Medicine, Seattle (MN); and the Tuberculosis Control Program, Public Health - Seattle & King County, Seattle, Washington (MN).
MD, MPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adelaide H. McClintock
From the Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington School of Medicine, Seattle (ME); the Division of General Internal Medicine, Department of Medicine, University of Washington School of Medicine, Seattle (AHM, AM); the Department of Oral Health Sciences, University of Washington School of Dentistry, Seattle (CMM); the Division of Pulmonary & Critical Care Medicine, Department of Medicine, University of Washington School of Medicine, Seattle (MN); and the Tuberculosis Control Program, Public Health - Seattle & King County, Seattle, Washington (MN).
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christy M. McKinney
From the Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington School of Medicine, Seattle (ME); the Division of General Internal Medicine, Department of Medicine, University of Washington School of Medicine, Seattle (AHM, AM); the Department of Oral Health Sciences, University of Washington School of Dentistry, Seattle (CMM); the Division of Pulmonary & Critical Care Medicine, Department of Medicine, University of Washington School of Medicine, Seattle (MN); and the Tuberculosis Control Program, Public Health - Seattle & King County, Seattle, Washington (MN).
PhD, MPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masahiro Narita
From the Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington School of Medicine, Seattle (ME); the Division of General Internal Medicine, Department of Medicine, University of Washington School of Medicine, Seattle (AHM, AM); the Department of Oral Health Sciences, University of Washington School of Dentistry, Seattle (CMM); the Division of Pulmonary & Critical Care Medicine, Department of Medicine, University of Washington School of Medicine, Seattle (MN); and the Tuberculosis Control Program, Public Health - Seattle & King County, Seattle, Washington (MN).
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexandra Molnar
From the Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington School of Medicine, Seattle (ME); the Division of General Internal Medicine, Department of Medicine, University of Washington School of Medicine, Seattle (AHM, AM); the Department of Oral Health Sciences, University of Washington School of Dentistry, Seattle (CMM); the Division of Pulmonary & Critical Care Medicine, Department of Medicine, University of Washington School of Medicine, Seattle (MN); and the Tuberculosis Control Program, Public Health - Seattle & King County, Seattle, Washington (MN).
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1.
    • Download figure
    • Open in new tab
    Figure 1.

    These are the numbers of patients with specific reasons for non-completion by treatment regimen. Being lost to follow-up was the most common reason for treatment non-completion. The most patients were lost to follow-up if they were treated with the longest regimen of isoniazid only.

  • Figure 2.
    • Download figure
    • Open in new tab
    Figure 2.

    These are the numbers of participants experiencing specific side effects by treatment regimen. Approximately one-third of patients reported at least one side effect.

Tables

  • Figures
    • View popup
    Table 1.

    Study Participant Demographics and Characteristics

    Noncompleters (n = 132)Completers (n = 259)P Value
    Age (years), mean41.644.6.06
    Sex
        Female53 (40.2)122 (47.1).19
        Male79 (59.9)137 (52.9)
    Treatment regimen
        Isoniazid and rifapentine13 (9.9)74 (28.6)<.001
        Rifampin alone12 (9.1)70 (27.0)
        Isoniazid alone107 (81.1)115 (44.4)
    Type of insurance*
        Private10 (8.7)49 (23.3)<.001
        Medicare/Medicaid/funded by government30 (26.1)45 (21.4)
        Charity/no insurance55 (47.8)107 (51.0)
        Other20 (17.4)9 (4.3)
    Race
        White11 (9.1)18 (7.1).10
        Black39 (32.2)55 (21.6)
        Asian46 (38.0)115 (45.1)
        Mexican/other Hispanic16 (13.2)32 (12.6)
        Pacific Islander5 (4.1)27 (10.6)
        Other4 (3.3)8 (3.1)
    Foreign born110 (90.2)230 (91.3).73
    English speaking66 (50.8)136 (53.3).63
    Marital status†
        Married48 (60.8)115 (73.7).04
        Unmarried/separated31 (39.2)41 (26.3)
    Homeless‡18 (15.0)26 (10.7).24
    Experienced side effects37 (28.0)94 (36.3).10
    Medical problems (n)
        047 (35.6)130 (50.2).01
        1–242 (31.8)77 (29.7)
        ≥343 (32.6)52 (20.1)
    Medications (n)
        0–145 (34.1)93 (35.9).86
        2–349 (37.1)89 (34.4)
        ≥338 (28.8)77 (29.7)
    Tobacco use23 (17.4)26 (10.0).04
    Alcohol use (>3 drinks, abuse, or dependence)25 (18.9)27 (10.4).02
    • Data are n (%) unless otherwise indicated. Also unless indicated, <5% of data was missing.

    • ↵* Missing data: 16.8%.

    • ↵† Missing data: 40.0%.

    • ↵‡ Missing data: 7.1%.

PreviousNext
Back to top

In this issue

The Journal of the American Board of Family     Medicine: 30 (4)
The Journal of the American Board of Family Medicine
Vol. 30, Issue 4
July-August 2017
  • Table of Contents
  • Table of Contents (PDF)
  • Cover (PDF)
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on American Board of Family Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Factors That Influence Treatment Completion for Latent Tuberculosis Infection
(Your Name) has sent you a message from American Board of Family Medicine
(Your Name) thought you would like to see the American Board of Family Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
3 + 6 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Factors That Influence Treatment Completion for Latent Tuberculosis Infection
McKenna C. Eastment, Adelaide H. McClintock, Christy M. McKinney, Masahiro Narita, Alexandra Molnar
The Journal of the American Board of Family Medicine Jul 2017, 30 (4) 520-527; DOI: 10.3122/jabfm.2017.04.170070

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Factors That Influence Treatment Completion for Latent Tuberculosis Infection
McKenna C. Eastment, Adelaide H. McClintock, Christy M. McKinney, Masahiro Narita, Alexandra Molnar
The Journal of the American Board of Family Medicine Jul 2017, 30 (4) 520-527; DOI: 10.3122/jabfm.2017.04.170070
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Conclusions
    • Acknowledgments
    • Notes
    • References
  • Figures & Data
  • References
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No smoke without fire: the impact of cigarette smoking on the immune control of tuberculosis
  • Content Usage and the Most Frequently Read Articles of 2017
  • In This Issue: Opiates, Tobacco, Social Determinants of Health, Social Accountability for Non-Profit Hospitals, More on PCMH, and Clinical Topics
  • Google Scholar

More in this TOC Section

  • Associations Between Modifiable Preconception Care Indicators and Pregnancy Outcomes
  • Perceptions and Preferences for Defining Biosimilar Products in Prescription Drug Promotion
  • Evaluating Pragmatism of Lung Cancer Screening Randomized Trials with the PRECIS-2 Tool
Show more Original Research

Similar Articles

Keywords

  • Antitubercular Agents
  • Isoniazid
  • Latent Tuberculosis
  • Motivation
  • Retrospective Studies
  • Rifampin
  • Rifapentine

Navigate

  • Home
  • Current Issue
  • Past Issues

Authors & Reviewers

  • Info For Authors
  • Info For Reviewers
  • Submit A Manuscript/Review

Other Services

  • Get Email Alerts
  • Classifieds
  • Reprints and Permissions

Other Resources

  • Forms
  • Contact Us
  • ABFM News

© 2025 American Board of Family Medicine

Powered by HighWire